Physician profile
James E Gallagher
NPI 1891962940
$7,510.54
in general payments reported to CMS, 2019-2025
32 companies · $1,724 in 2025
The $1,724 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,004 · 2022: $1,043 · 2023: $1,280 · 2024: $1,460 · 2025: $1,724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,463.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,529.24 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $684.77 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $553.52 | 2024-2025 | Voquezna |
| Pfizer INC. | $546.67 | 2021-2025 | |
| Abbvie INC. | $463.69 | 2021-2025 | |
| Dexcom, INC. | $336.39 | 2023-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $329.52 | 2021-2022 | |
| Novo Nordisk INC | $322.03 | 2021-2025 | Wegovy |
| Amgen INC. | $285.21 | 2024-2025 | Otezla, Repatha, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $191.85 | 2023-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $135.71 | 2025 | |
| Glaxosmithkline, LLC. | $135.30 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Biohaven Pharmaceuticals, INC. | $117.96 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.88 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $97.18 | 2021-2023 | Emgality, Jardiance, Reyvow |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $72.75 | 2023-2025 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $69.42 | 2021-2023 | M-M-R II, Gardasil 9, Vaxelis |
| Takeda Pharmaceuticals U.S.A., INC. | $65.27 | 2021 | |
| Novartis Pharmaceuticals Corporation | $58.70 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $56.60 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $53.35 | 2024-2025 | |
| Astellas Pharma US INC | $44.12 | 2021-2024 | Veozah |
| Exact Sciences Corporation | $40.47 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Aprecia Pharmaceuticals, LLC | $36.23 | 2023 | Spritam |
| Actelion Pharmaceuticals US, INC. | $34.00 | 2025 | Opsumit, Uptravi |
| Otsuka America Pharmaceutical, INC. | $25.03 | 2023 | Rexulti |
| Sk Life Science, INC. | $24.61 | 2022 | |
| Amneal Pharmaceuticals LLC | $22.00 | 2025 | Unithroid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.09 | 2022 | |
| Mylan Specialty L.P. | $15.96 | 2023 | Yupelri |
| Insulet Corporation | $15.48 | 2025 | Omnipod |
| Athena Bioscience, LLC | $14.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Gallagher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.